Last Friday, the FDA approved RYDAPT
(midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy.
Today, McKesson Specialty Health oncology pharmacy services company Biologics, Inc. announced that it has been selected by Norvatis to be in the distribution network for the drug.
FLT3-mutated AML is both rare and aggressive, and its approach to treatment has remained relatively stagnant for more than a quarter century. Because of this, the creation and commercialization of RYDAPT is a welcomed progression in cancer care, and gives healthcare providers an alternative treatment option for the disease.
About Acute Myeloid Leukemia:
Acute myeloid leukemia (AML) is a form of cancer in which the bone marrow makes irregular myeloblasts. Symptoms include fatigue, recurrent infections and easy bruising. Acute myeloid leukemia is typically found in the older population and is uncommon in people younger than 45.
The National Cancer Institute estimated that approximately 19,930 people would be diagnosed with AML in 2016 and 10,430 expected to die of the disease. AML has previously been treated with chemotherapy.
About Biologics, Inc.:
: Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.